Sigyn Therapeutics, Inc. (OTCMKTS:SIGY – Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 1,994 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily trading volume, of 13,955 shares, the short-interest ratio is presently 0.1 days.
Sigyn Therapeutics Stock Down 8.6%
Sigyn Therapeutics stock opened at $0.03 on Friday. The stock has a market cap of $70,612.00, a price-to-earnings ratio of -0.01 and a beta of -0.04. Sigyn Therapeutics has a 12-month low of $0.01 and a 12-month high of $2.00. The business’s 50-day simple moving average is $0.03 and its 200 day simple moving average is $0.12.
Sigyn Therapeutics Company Profile
Sigyn Therapeutics, Inc is a biotechnology and medical device company focused on developing therapeutic solutions for cancer and pathogen-associated diseases. The company’s primary technology is designed to address conditions in which harmful pathogens and excessive inflammatory signaling contribute to disease progression.
Its lead product candidate, Sigyn Therapy, is an extracorporeal blood-purification technology intended to remove circulating pathogens and inflammatory cytokines from a patient’s blood.
See Also
- Five stocks we like better than Sigyn Therapeutics
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
